Keyphrases
Transforming Growth Factor-β
100%
Bevacizumab
79%
Open Globe Injury
78%
Treatment Group
76%
Pseudomonas Aeruginosa Keratitis
75%
Interleukin-1β
75%
Apoptosis
65%
Triamcinolone Acetonide
63%
Rattus Norvegicus
59%
Epigallocatechin Gallate
50%
Retinal Ganglion Cells
50%
Collagen Expression
50%
Matrix metalloproteinase-9 (MMP-9)
50%
Type I Collagen
50%
Tumor Necrosis Factor-α
50%
Injury Model
50%
Plasminogen Activator inhibitor-1 (PAI-1)
50%
Catalase
50%
Lens Epithelial Cells
50%
Fibrosis
47%
Cornea
46%
Wound Healing
43%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
41%
Superoxide Dismutase 2 (SOD2)
40%
Adjuvant Therapy
38%
Cell Proliferation
38%
Platelet-rich Fibrin
37%
Intravitreal Ranibizumab
31%
Morphological Changes
31%
Growth Factors
31%
Platelet-rich Fibrin Membrane
31%
Intraocular Pressure
30%
Rabbit Eye
30%
Cellular Expression
30%
Ocular Trauma
30%
Phacoemulsification
30%
Human Lens Epithelial Cells
30%
Proliferative Vitreoretinopathy
30%
Experimental Facility
30%
Glaucoma
29%
Matrix Metalloproteinases
28%
Oryctolagus Cuniculus
28%
Sodium Hydroxide
27%
Intravitreal
27%
Sclera
27%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
27%
Corticosteroids
27%
α-smooth muscle Actin (α-SMA)
27%
Human Pterygium Fibroblasts
25%
In Vitro Approach
25%
Pharmacology, Toxicology and Pharmaceutical Science
Triamcinolone Acetonide
77%
Bevacizumab
77%
Interleukin 1
75%
Keratitis
75%
Pseudomonas aeruginosa
75%
Transforming Growth Factor Beta
75%
Tumor Necrosis Factor
65%
Vasculotropin
56%
Epigallocatechin Gallate
50%
Platelet-Rich Fibrin
50%
Gelatinase B
50%
Plasminogen Activator Inhibitor 1
50%
Wound Healing
49%
Leporidae
48%
Eye Injury
37%
Treatment Group
36%
Intravitreal Administration
35%
Vitreoretinopathy
32%
Cornea Injury
31%
Rattus norvegicus
31%
Glaucoma
30%
Fibrosis
28%
Matrix Metalloproteinase
28%
Inflammation
28%
Eye Disease
28%
Pterygium
25%
Mitomycin
25%
Fibrin Glue
25%
Penetrating Trauma
25%
Copper Zinc Superoxide Dismutase
25%
Heat Shock Protein 27
25%
Diabetic Macular Edema
25%
Catalase
25%
microRNA
25%
Biological Marker
25%
Superoxide Dismutase
25%
Dry Eye
25%
microRNA 126
25%
Smooth Muscle Actin
25%
Interleukin 10
25%
Heat Shock Protein 70
25%
Curcumin
25%
Interleukin 6
25%
Alteplase
25%
Collagen Type 1
22%
Moxifloxacin
18%
Gelatinase A
16%
Tissue Inhibitor of Metalloproteinase
16%
Diseases
15%
Wound
13%
Medicine and Dentistry
Bevacizumab
75%
Pseudomonas aeruginosa
75%
Keratitis
75%
Epithelial Cell
55%
In Vitro
54%
Fibrosis
51%
Epigallocatechin Gallate
50%
Triamcinolone Acetonide
50%
Transforming Growth Factor Beta
50%
Interleukin 1
50%
Gelatinase B
50%
Programmed Cell Death
50%
Treatment Group
46%
Collagen Type 1
40%
Tumor Necrosis Factor
40%
Adjuvant Therapy
38%
Intraocular Pressure
35%
Fibroblast
32%
Eye Injury
30%
Matrix Metalloproteinase
28%
Penetrating Trauma
25%
Corneal Wound Healing
25%
Heat Shock Protein 27
25%
Copper Zinc Superoxide Dismutase
25%
Visual Acuity
25%
Ganglion
25%
Platelet-Rich Fibrin
25%
Glycon
25%
Biological Marker
25%
Catalase
25%
Phacoemulsification
25%
Mitomycin
25%
Trabeculectomy
25%
Fibrin Glue
25%
Superoxide Dismutase
25%
Smooth Muscle Actin
25%
Pterygium
25%
Interleukin 10
25%
Curcumin
25%
Eye Disease
25%
Dry Eye
25%
Cell Proliferation
25%
Senile Cataract
25%
Plasminogen Activator Inhibitor-1
25%
Cancer Growth Factor
25%
Cataract
25%
Alteplase
25%
Moxifloxacin
18%
Immunohistochemistry
17%
Heat Shock Protein 70
17%